This computational biomarker can help with the rapid diagnosis of epilepsy
Assessing susceptibility to Epilepsy
This 'seizure susceptibility' measure can serve as both a biomarker of idiopathic generalised epilepsy and also as a means of gaining a statistical measure of the efficacy of any administered anti-epilepsy drug (AED).
The method gives a statistical probability of seizure, based on a computational model of the results of EEG analysis.
- Can provide an objective measure for diagnosing epilepsy. Current diagnosis is subjective to clinician’s expertise, witness account and subjective interpretation of EEG, MRI readouts.
- Diagnosis can be rapid. Current practice leads to a delay in providing AED medication to patients with epilepsy.
- Reduction of falsely diagnosed patients will lead to fewer people taking medication unnecessarily.
- Diagnosis of epileptic seizures in patients more rapidly and accurately than present.
- Prognostic tool to determine the efficacy of a particular AED over a much more rapid timescale than current methods which trial and error test.
A PCT patent application has been submitted PCT/GB2013/051485
The University is keen to discuss potential partnerships with a view to collaborations to develop a commercially available product